keyword
MENU ▼
Read by QxMD icon Read
search

Review nhl treatment

keyword
https://www.readbyqxmd.com/read/28203178/a-patient-with-supraclavicular-lymphadenopathy-and-anterior-mediastinal-mass-presenting-as-a-rare-case-of-composite-lymphoma-a-case-report-and-literature-review
#1
Alex Raufi, James Jerkins, Yung Lyou, Deepa Jeyakumar
Composite lymphoma (CL) is a rare disease with 2 distinct lymphomas concurrently arising in a single patient with an estimated incidence of 1-4.7% of newly diagnosed lymphomas per year. CL most commonly involves 2 B-cell non-Hodgkin lymphomas (NHL) or a B-cell NHL with a Hodgkin lymphoma. Our case is unique in that it was a bilineage CL with both a T-cell and B-cell NHL, which has only been reported in a few case reports. A 49-year-old woman presented with several months of progressive cough, weight loss, dyspnea, and supraclavicular lymphadenopathy...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/28197753/asparaginase-pharmacology-challenges-still-to-be-faced
#2
REVIEW
Claudia Lanvers-Kaminsky
PURPOSE: The benefits of asparaginase (ASNASE) in the treatment of ALL and NHL are indisputable and new ASNASE preparations are under clinical development to overcome limitations of the actual ASNASE therapy, especially immunogenicity. Apart from ALL and NHL further indications of ASNASE are preclinically and clinically evaluated. METHODS: We reviewed ASNASE literature and especially focused on the mechanism of action, on biomarker, which determine ASNASE sensitivity and resistance, and on ASNASE pharmacodynamics in vivo...
February 14, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28191800/primary-thyroid-lymphoma-clinicopathologic-characteristics-and-therapeutic-outcomes-of-six-cases-in-morocco
#3
(no author information available yet)
BACKGROUND: Primary non-Hodgkin lymphomas of the thyroid are uncommon and account for 1-5% of all thyroid malignancies and less than 2% of extranodal lymphomas. The aim of the present study was to review our experience and management of primary thyroid lymphoma and to discuss the diagnostic and therapeutic considerations. METHODS: All non-Hodgkin lymphoma diagnosed at our institution between 2007 and 2011 were reviewed, six cases of primary thyroid lymphoma were identified...
September 2016: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/28191314/diagnosis-and-treatment-of-cd20-negative-b-cell-lymphomas
#4
REVIEW
Tasleem Katchi, Delong Liu
CD20 negative B cell non-Hodgkin lymphoma (NHL) is rare and accounts for approximately 1-2% of B cell lymphomas. CD20- negative NHL is frequently associated with extranodal involvement, atypical morphology, aggressive clinical behaviour, resistance to standard chemotherapy and poor prognosis. The most common types of these include plasmablastic lymphoma, primary effusion lymphoma, large B-cell lymphoma arising from HHV8-associated multicentric Castleman's disease, and ALK+ large B cell lymphoma. This review provides an overview of the diagnostic and treatment modalities for CD20 negative B cell NHL...
2017: Biomarker Research
https://www.readbyqxmd.com/read/28184292/rituximab-therapy-in-pemphigus-and-other-autoantibody-mediated-diseases
#5
REVIEW
Nina A Ran, Aimee S Payne
Rituximab, a monoclonal antibody targeting the B cell marker CD20, was initially approved in 1997 by the United States Food and Drug Administration (FDA) for the treatment of non-Hodgkin lymphoma. Since that time, rituximab has been FDA-approved for rheumatoid arthritis and vasculitides, such as granulomatosis with polyangiitis and microscopic polyangiitis. Additionally, rituximab has been used off-label in the treatment of numerous other autoimmune diseases, with notable success in pemphigus, an autoantibody-mediated skin blistering disease...
2017: F1000Research
https://www.readbyqxmd.com/read/28182089/a-rare-case-of-signet-ring-cell-lymphoma-diagnosis-aided-by-immunofluorescent-staining
#6
Charusheela R Gore, N K Panicker, Harsh Kumar, Archana Buch, S S Chandanwale
Signet ring cell lymphomas are the proliferations of malignant lymphoid cells containing cytoplasmic vacuoles or globules which displace the nuclei, imparting it a signet ring appearance. This rare tumor is a variant of non-Hodgkin lymphoma. Signet ring appearance is due to cytoplasmic accumulation of immunoglobulin or vacuoles derived from multivesicular bodies. These cells, particularly with cytoplasmic vacuoles, may be mistaken for adenocarcinoma cells. We are presenting one such case where immunofluorescence helped us to demonstrate the immunoglobulins on fine needle aspiration smears...
January 2017: Journal of Cytology
https://www.readbyqxmd.com/read/28152659/development-of-primary-central-nervous-system-lymphoma-in-a-systemic-lupus-erythematosus-patient-after-treatment-with-mycophenolate-mofetil-and-review-of-the-literature
#7
M A Balci, G E Pamuk, E Unlu, U Usta, O N Pamuk
Primary central nervous system lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma and four cases of PCNSL have previously been described in association with mycophenolate mofetil. We report the fifth case of PCNSL in a patient with lupus nephropathy while on mycophenolate mofetil treatment.
January 1, 2017: Lupus
https://www.readbyqxmd.com/read/28146265/m-tor-inhibitors-and-their-potential-role-in-haematological-malignancies
#8
REVIEW
Teresa Calimeri, Andrés J M Ferreri
It is widely demonstrated that the PI3K-AKT-mTOR signalling is critical in normal myeloid and lymphoid development and function. Thus, it is not strange that this pathway is often deregulated in haematological tumours, providing a strong preclinical rationale for the use of drugs targeting the PI3K-AKT-mTOR axis in haematological malignancies. The main focus of this review is to examine the mammalian target of rapamycin (mTOR, also termed mechanistic target of rapamycin [MTOR]) signalling pathways and to provide a brief overview of rapalogs and second-generation mTOR inhibitors used to target its aberrant activation in cancer treatment...
February 1, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28140709/recent-advances-and-future-directions-in-mantle-cell-lymphoma-research-report-of-the-2016-mantle-cell-lymphoma-consortium-workshop
#9
Brad S Kahl, Martin Dreyling, Leo I Gordon, Leticia Quintanilla-Martinez, Eduardo M Sotomayor
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma typically associated with the t(11;14) chromosomal translocation, resulting in overexpression of cyclin D1. Although MCL is associated with clinical heterogeneity, outcomes are generally poor and no standard treatment has been established. However, the recent approval of ibrutinib provides a new therapeutic option. Moreover, recent clinical trials have provided new perspectives on the relative efficacy and safety of various approaches for both transplant-eligible and transplant-ineligible patients...
January 31, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28140702/antiviral-therapies-for-managing-viral-hepatitis-in-lymphoma-patients
#10
Michele Merli, Sara Rattotti, Manuel Gotti, Luca Arcaini
In patients with lymphoma the detection of positive hepatitis B or C viruses (HBV and HCV) serology involves crucial therapeutic consequences. In HBV-infected patients the serological profile of active (HBsAg-positive) or resolved (HBsAg-negative/anti-HBcAb-positive) infection is associated to differential risk of viral reactivation during rituximab-based therapy and require appropriate strategies of monitoring and of antiviral prophylaxis. In HCV-associated NHL patients consolidated data demonstrated that interferon (IFN)-based antiviral therapy (AT) is able to induce lymphoma regression strictly related to viral eradication, while preliminary data of the new direct-acting antivirals (DAAs) are very promising...
January 31, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28140696/siltuximab-and-hematologic-malignancies-a-focus-in-non-hodgkin-lymphoma
#11
Andrea Ferrario, Michele Merli, Claudia Basilico, Margherita Maffioli, Francesco Passamonti
The role of interleukin-6 (IL-6) in tumorigenesis and in particular in haematological malignancies is crucial. On the basis of the favourable results obtained in the subset of multicentric Castleman disease (MCD), Siltuximab, a chimeric, human-murine, immunoglobulin (Ig) Gk monoclonal antibody directed against human IL-6 has been evaluated in haematological malignancies such as multiple myeloma, myelodisplastic syndromes and non Hodgkin lymphomas. Areas covered: This review discusses available data related to the role of IL-6 as a therapeutic target, the characteristics of Siltuximab in term pharmacokinetics and pharmacodynamics properties and a detailed analysis of the studies involving haematological malignancies with a peculiar focus on non Hodgkin lymphoma...
January 31, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28127387/clinical-and-prognostic-analysis-of-78-patients-with-human-immuno-deficiency-virus-associated-non-hodgkin-s-lymphoma-in-chinese-population
#12
Yang Shen, Renfang Zhang, Li Liu, Yinzhong Shen, Wei Song, Tangkai Qi, Yang Tang, Zhenyan Wang, Liqian Guan, Hongzhou Lu
BACKGROUND: Human Immuno-deficiency Virus (HIV) associated non-Hodgkin's lymphoma (NHL) was a special group of disease, which manifests distinct clinical features and prognosis as compared with NHLs in patients without HIV. We performed this study to describe the clinical features of the disease and investigated the potential prognostic factors. METHODS: HIV-infected patients who were newly diagnosed with NHL were enrolled in this study. The selection of anti-lymphoma treatment regimen was mainly dependent on the pathological subtypes of NHLs...
2017: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/28122468/kshv-associated-extracavitary-primary-effusion-lymphoma-in-an-hiv-seronegative-patient-a-case-report-and-review-of-the-literature
#13
Uroosa Ibrahim, Amina Saqib, Farhan Mohammad, Juan Ding, Shafinaz Hussein, Jean Paul Atallah
Primary effusion lymphoma (PEL) is a rare type of non-Hodgkin's lymphoma presenting as a lymphomatous effusion and absence of a solid tumor mass. Extracavitary PEL (EC-PEL) is a subtype of PEL with the absence of an effusion but presence of solid tumor. PEL and EC-PEL share the same histopathologic and immunophenotypic features. Kaposi sarcoma-associated herpesvirus (KSHV) positivity is seen universally in these malignancies and is a requisite for diagnosis. Most cases are seen to occur in HIV positive individuals...
January 26, 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/28120776/clinical-characteristics-differential-diagnosis-and-treatment-outcome-of-subcutaneous-panniculitis-like-t-cell-lymphoma-a-literature-review-of-published-japanese-cases
#14
Mikio Ohtsuka, Takako Miura, Toshiyuki Yamamoto
BACKGROUND: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of non-Hodgkin lymphoma that shows phenotypic features of cytotoxic T cells and preferentially involves subcutaneous tissue. SPTCL is believed to show an indolent clinical course, unless patients develop haemophagocytic syndrome. Various reported therapies include corticosteroids, immunosuppressive drugs, and chemotherapies. The use of chemotherapy as a first-line treatment remains controversial, and treatment approaches for SPTCL have not been established yet...
February 1, 2017: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/28112752/carmustine-replacement-in-intensive-chemotherapy-preceding-reinjection-of-autologous-hscs-in-hodgkin-and-non-hodgkin-lymphoma-a-review
#15
REVIEW
G Damaj, J Cornillon, K Bouabdallah, R Gressin, S Vigouroux, T Gastinne, F Ranchon, H Ghésquières, G Salles, I Yakoub-Agha, E Gyan
High-dose chemotherapy preceding autologous hematopoietic stem cell transplantation (auto-HSCT) is one treatment option for patients with Hodgkin (HL) or non-Hodgkin lymphoma (NHL). The most frequently used intensive chemotherapy is a combination of carmustine (BCNU), etoposide, cytarabine and melphalan (BEAM). However, BCNU is consistently in short supply, and there has been a recent dramatic increase in its cost, necessitating the utilization of conditioning alternatives. The busulfan-based conditioning regimen known as the busulfan-cyclophosphamide-etoposide (BuCyE) combination is the second most-studied conditioning regimen worldwide after BEAM, and it exhibits a benefit/risk ratio that is comparable to that of BEAM...
January 23, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28096718/diffuse-large-b-cell-lymphoma-in-the-era-of-precision-oncology-how-imaging-is-helpful
#16
REVIEW
Hina J Shah, Abhishek R Keraliya, Jyothi P Jagannathan, Sree Harsha Tirumani, Vikram R Lele, Pamela J DiPiro
Diffuse large B cell lymphoma (DLBCL) is the most common histological subtype of Non-Hodgkin's lymphoma. As treatments continues to evolve, so do imaging strategies, and positron emission tomography (PET) has emerged as the most important imaging tool to guide oncologists in the diagnosis, staging, response assessment, relapse/recurrence detection,and therapeutic decision making of DLBCL. Other imaging modalities including magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, and conventional radiography are also used in the evaluation of lymphoma...
January 2017: Korean Journal of Radiology: Official Journal of the Korean Radiological Society
https://www.readbyqxmd.com/read/28094575/treatment-approaches-of-hard-to-treat-non-hodgkin-lymphomas
#17
Lakshminarayanan Nandagopal, Amitkumar Mehta
Even after recent advancements with monoclonal antibodies, antibody drug conjugates and immune therapies, relapsed and refractory lymphomas remain challenging to treat; and the definition and treatment approaches of hard-to-treat lymphomas (HTL) continue to evolve. Areas covered: In this review, we will address HTL encompassing diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL) and peripheral T cell lymphomas (PTCL). DLBCL, which comprises 30-40% of non-Hodgkin lymphomas is a highly aggressive and heterogeneous malignancy, with primary refractory or relapsed disease remaining a therapeutic challenge...
January 17, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28067179/cd20-based-immunotherapy-of-b-cell-derived-hematologic-malignancies
#18
Dariush Shanehbandi, Jafar Majidi, Tohid Kazemi, Behzad Baradaran, Leili Aghebati-Maleki
CD20 is a surface antigen which is expressed at certain stages of B-cell differentiation. Targeting the CD20-positive B-cells with therapeutic monoclonal antibodies (MAbs) has been an effectual strategy in the treatment of hematologic malignancies such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Initial success with Rituximab (RTX) has encouraged the creation and development of more effective CD20 based therapeutics. However, treatment with conventional MAbs has not been adequate to overcome the problems such as refractory/relapsed disease...
January 9, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28061982/pi3k-signaling-pathway-in-normal-b-cells-and-indolent-b-cell-malignancies
#19
REVIEW
Georgios Pongas, Bruce D Cheson
In chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs), B-cell receptor signaling leads to activation of the phosphatidylinositol 3-kinase (PI3K) pathway. Idelalisib, a PI3Kδ inhibitor was approved in 2014 by the US Food and Drug Administration (FDA) in combination with rituximab for the treatment of patients with CLL for whom single-agent rituximab would be considered appropriate and as a single agent for patients with relapsed small lymphocytic lymphoma (SLL) and relapsed follicular lymphoma (FL)...
December 2016: Seminars in Oncology
https://www.readbyqxmd.com/read/28040682/t-cell-lymphoma-recent-advances-in-characterization-and-new-opportunities-for-treatment
#20
REVIEW
Carla Casulo, Owen O'Connor, Andrei Shustov, Michelle Fanale, Jonathan W Friedberg, John P Leonard, Brad S Kahl, Richard F Little, Lauren Pinter-Brown, Ranjani Advani, Steven Horwitz
Peripheral T-cell lymphomas (PTCLs) are uncommon, heterogeneous, and aggressive non-Hodgkin's lymphomas. Despite progress in the last several years resulting in a deeper understanding of PTCL biology and pathogenesis, there is currently no accepted single standard of care for newly diagnosed patients, and for those with relapsed or refractory disease, prognosis is dismal. The National Cancer Institute convened a Clinical Trials Planning Meeting to advance the national clinical trial agenda in lymphoma. The objective was to identify unmet needs specific to five major lymphoma subtypes and develop strategies to address them...
February 2017: Journal of the National Cancer Institute
keyword
keyword
19119
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"